GlobeNewswire·Sep 9, 2026, 7:45 AM ET

Serina Therapeutics Reports Cohort 1 Observations from SER-252 Registrational Study in Advanced Parkinson’s Disease and Advances to Cohort 2

The Independent Safety Monitoring Committee recommended advancing SER-252 to Cohort 2 following a blinded review of Cohort 1 safety & tolerability data.
Blinded observations at the lowest dose showed a pharmacokinetic profile consistent with the sustained apomorphine exposure the drug is designed to provide.
Individual patients in Cohort 1 demonstrated sustained periods of motor function improvement on exploratory clinical measures.
Cohort 1 enrolled eight patients with Parkinson's disease & motor fluctuations who were randomized 3:1 to receive SER-252 or placebo.
Patients were withdrawn from background Parkinson's medications during the study to characterize the pharmacokinetic profile & observe motor function changes.
SER-252 is an investigational long-acting apomorphine formulation enabled by Serina's proprietary POZ technology designed for continuous dopaminergic stimulation.
The Phase 1b registrational study is a randomized, double-blind, placebo-controlled trial conducted across sites in the U.S., Australia, South Korea, & Taiwan.
Serina expects to report topline data from the single-ascending-dose portion of the study in the first half of 2027.